Piperazine Oxadiazole Inhibitors of Acetyl-CoA Carboxylase

被引:17
作者
Bourbeau, Matthew P. [1 ]
Siegmund, Aaron [1 ]
Allen, John G. [1 ]
Shu, Hong [1 ]
Fotsch, Christopher [1 ]
Bartberger, Michael D. [1 ]
Kim, Ki-Won [2 ]
Komorowski, Renee [2 ]
Graham, Melissa [2 ]
Busby, James [2 ,3 ]
Wang, Minghan [2 ,3 ]
Meyer, James [3 ]
Xu, Yang
Salyers, Kevin
Fielden, Mark [4 ]
Veniant, Murielle M. [2 ]
Gu, Wei [2 ]
机构
[1] Amgen Inc, Therapeut Discovery, Thousand Oaks, CA 91320 USA
[2] Amgen Inc, Metab Dis Res, Thousand Oaks, CA 91320 USA
[3] Amgen Inc, Pharmacokinet Drug Metab, Thousand Oaks, CA 91320 USA
[4] Amgen Inc, Comparat Biol & Safety Sci, Thousand Oaks, CA 91320 USA
关键词
FATTY-ACID OXIDATION; ENERGY-EXPENDITURE; METABOLIC-SYNDROME; MUTANT MICE; DESIGN; KNOCKOUT; MASS;
D O I
10.1021/jm401601s
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Acetyl-CoA carboxylase (ACC) is a target of interest for the treatment of metabolic syndrome. Starting from a biphenyloxadiazole screening hit, a series of piperazine oxadiazole ACC inhibitors was developed. Initial pharmacokinetic liabilities of the piperazine oxadiazoles were overcome by blocking predicted sites of metabolism, resulting in compounds with suitable properties for further in vivo studies. Compound 26 was shown to inhibit malonyl-CoA production in an in vivo pharmacodynamic assay and was advanced to a long-term efficacy study. Prolonged dosing with compound 26 resulted in impaired glucose tolerance in diet-induced obese (DIO) CS7BL6 mice, an unexpected finding.
引用
收藏
页码:10132 / 10141
页数:10
相关论文
共 31 条
[1]   Mutant mice lacking acetyl-CoA carboxylase 1 are embryonically lethal [J].
Abu-Elheiga, L ;
Matzuk, MM ;
Kordari, P ;
Oh, W ;
Shaikenov, T ;
Gu, ZW ;
Wakil, SJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (34) :12011-12016
[2]   Acetyl-CoA carboxylase 2 mutant mice are protected against obesity and diabetes induced by high-fat/high-carbohydrate diets [J].
Abu-Elheiga, L ;
Oh, WK ;
Kordari, P ;
Wakil, SJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (18) :10207-10212
[3]   Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2 [J].
Abu-Elheiga, L ;
Matzuk, MM ;
Abo-Hashema, KAH ;
Wakil, SJ .
SCIENCE, 2001, 291 (5513) :2613-2616
[4]   A new class of easily activated palladium precatalysts for facile C-N cross-coupling reactions and the low temperature oxidative addition of aryl chlorides [J].
Biscoe, Mark R. ;
Fors, Brett P. ;
Buchwald, Stephen L. .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2008, 130 (21) :6686-+
[5]  
Bjorntorp Per, 1994, Current Opinion in Lipidology, V5, P166, DOI 10.1097/00041433-199405030-00003
[6]  
Bourbeau M. P., 2012, NEW THERAPEUTIC STRA, P464
[7]   Recent Advances in Acetyl-CoA Carboxylase Inhibitors [J].
Bourbeau, Matthew P. ;
Allen, John G. ;
Gu, Wei .
ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 45, 2010, 45 :95-108
[8]   Continuous fat oxidation in acetyl-CoA carboxylase 2 knockout mice increases total energy expenditure, reduces fat mass, and improves insulin sensitivity [J].
Choi, Cheol Soo ;
Savage, David B. ;
Abu-Elheiga, Lutfi ;
Liu, Zhen-Xiang ;
Kim, Sheene ;
Kulkarni, Ameya ;
Distefano, Alberto ;
Hwang, Yu-Jin ;
Reznick, Richard M. ;
Codella, Roberto ;
Zhang, Dongyan ;
Cline, Gary W. ;
Wakil, Salih J. ;
Shulman, Gerald I. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (42) :16480-16485
[9]   Review of recent acetyl-CoA carboxylase inhibitor patents: mid-2007-2008 [J].
Corbett, Jeffrey W. .
EXPERT OPINION ON THERAPEUTIC PATENTS, 2009, 19 (07) :943-956
[10]   MetaSite: Understanding metabolism in human cytochromes from the perspective of the chemist [J].
Cruciani, G ;
Carosati, E ;
De Boeck, B ;
Ethirajulu, K ;
Mackie, C ;
Howe, T ;
Vianello, R .
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (22) :6970-6979